Ketoconazole doubles the AUC of
rimonabant. Other drugs that are potent inhibitors of CYP3A4, such as
clarithromycin and
telithromycin, are predicted to interact similarly. Note that the
macrolides differ in their ability to inhibit CYP3A4, see
macrolides.
The manufacturers of
rimonabant recommend caution. Monitor for signs of
increased
rimonabant adverse effects.